Comparative Pharmacology
Head-to-head clinical analysis: HEPATASOL 8 versus TRAVASOL 10 W O ELECTROLYTES.
Head-to-head clinical analysis: HEPATASOL 8 versus TRAVASOL 10 W O ELECTROLYTES.
HEPATASOL 8% vs TRAVASOL 10% W/O ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Travasol 10% w/o electrolytes is a parenteral nutrition solution containing essential and non-essential amino acids. The amino acids provide substrates for protein synthesis, thereby supporting tissue repair, growth, and maintenance. The solution also provides a source of nitrogen and caloric replacement.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
10% amino acid solution administered intravenously via central line at 0.5-1.0 g amino acids/kg/day, not to exceed 2.5 g/kg/day; typical infusion rate 50-125 mL/hr.
None Documented
None Documented
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
The terminal elimination half-life of infused amino acids is approximately 1-2 hours, reflecting rapid metabolism and clearance. Clinical context: Steady state is achieved within 1-2 hours of continuous infusion.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Amino acids are primarily metabolized; nitrogen is excreted renally as urea (∼85-90%), with small amounts in feces (∼5%) and minimal biliary elimination. Electrolytes are excreted renally, with excretion proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution